Richard A. Colvin

3.5k total citations
51 papers, 2.3k citations indexed

About

Richard A. Colvin is a scholar working on Genetics, Immunology and Molecular Biology. According to data from OpenAlex, Richard A. Colvin has authored 51 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 15 papers in Immunology and 10 papers in Molecular Biology. Recurrent topics in Richard A. Colvin's work include Hemoglobinopathies and Related Disorders (15 papers), Chemokine receptors and signaling (10 papers) and Acute Lymphoblastic Leukemia research (5 papers). Richard A. Colvin is often cited by papers focused on Hemoglobinopathies and Related Disorders (15 papers), Chemokine receptors and signaling (10 papers) and Acute Lymphoblastic Leukemia research (5 papers). Richard A. Colvin collaborates with scholars based in United States, France and United Kingdom. Richard A. Colvin's co-authors include Andrew D. Luster, Gabriele Campanella, Mariano A. García-Blanco, Seddon Y. Thomas, Andrew M. Tager, Israel Charo, Sabina A. Islam, Bernhard Moser, Michelle L. McCully and Sérgio A. Lira and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Richard A. Colvin

49 papers receiving 2.3k citations

Peers

Countries citing papers authored by Richard A. Colvin

Since Specialization

Citations

This map shows the geographic impact of Richard A. Colvin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard A. Colvin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard A. Colvin more than expected).

Fields of papers citing papers by Richard A. Colvin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard A. Colvin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard A. Colvin. The network helps show where Richard A. Colvin may publish in the future.

Co-authorship network of co-authors of Richard A. Colvin

This figure shows the co-authorship network connecting the top 25 collaborators of Richard A. Colvin. A scholar is included among the top collaborators of Richard A. Colvin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard A. Colvin. Richard A. Colvin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial 2024 ·The Lancet ·Janet L. Kwiatkowski, Mark C. Walters, Suradej Hongeng, (unknown), Andreas E. Kulozik, Joachim B. Kunz, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Tao Ge, (unknown), (unknown), Heidi Elliot, (unknown), Ji Hyun Lee, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson	14
2	Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent β-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies 2021 ·Transplantation and Cellular Therapy ·Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Ruiting Guo, Weijian Liu, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson	1
3	Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion 2021 ·Transplantation and Cellular Therapy ·Suradej Hongeng, Alexis A. Thompson, Janet L. Kwiatkowski, Franco Locatelli, John B. Porter, John E.J. Rasko, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Andreas E. Kulozik, Evangelia Yannaki, Manfred Schmidt, (unknown), Ruiting Guo, Weijian Liu, Richard A. Colvin, Mark C. Walters	1
4	Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up 2021 ·Blood ·Alexis A. Thompson, Franco Locatelli, Evangelia Yannaki, Mark C. Walters, John B. Porter, Suradej Hongeng, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Marina Cavazzana, (unknown), Lin Du, Richard A. Colvin, Janet L. Kwiatkowski	2
5	Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia 2020 ·Blood ·Alexis A. Thompson, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Ruiting Guo, Weijian Liu, Richard A. Colvin, Mark C. Walters, Franco Locatelli	7
6	Long-Term Efficacy and Safety of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia: Results in Patients with up to 6 Years of Follow-up 2020 ·Blood ·Janet L. Kwiatkowski, Mark C. Walters, Suradej Hongeng, Franco Locatelli, (unknown), Marina Cavazzana, Ying Chen, Richard A. Colvin, Alexis A. Thompson	8
7	Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ TH2 cells 2011 ·Nature Immunology ·Sabina A. Islam, (unknown), Richard A. Colvin, (unknown), Michelle L. McCully, Bernhard Moser, Sérgio A. Lira, Israel Charo, Andrew D. Luster	229
8	Movement within and movement beyond 2011 ·Cell Adhesion & Migration ·Richard A. Colvin, Andrew D. Luster	2
9	Synaptotagmin-mediated vesicle fusion regulates cell migration 2010 ·Nature Immunology ·Richard A. Colvin, Terry K. Means, Thomas Diefenbach, Luís F. Moita, (unknown), Sanja Sever, Gabriele Campanella, (unknown), (unknown), Catarina Moita, Norma W. Andrews, Dianqing Wu, Nir Hacohen, Andrew D. Luster	88
10	Evolutionarily Conserved Recognition and Innate Immunity to Fungal Pathogens by the Scavenger Receptors SCARF1 and CD36 2009 ·Digital Access to Scholarship at Harvard (DASH) (Harvard University) ·Emmanouil Tampakakis, Lindsay Puckett, Melissa Tai, Cameron R. Stewart, Suzanne E. Hickman, Kathryn J. Moore, (unknown), Terry K. Means, Eleftherios Mylonakis, Richard A. Colvin, Edward Seung, Read Pukkila-Worley, Stephen B. Calderwood, Nir Hacohen, Andrew D. Luster	195
11	Kynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions 2009 ·Journal of Biological Chemistry ·(unknown), Neil Ahluwalia, Thomas J.T. Anderson, Gregory J. Hardy, Sumita Sinha, Jose Alvarez‐Cardona, (unknown), Eugene P. Rhee, Richard A. Colvin, Robert E. Gerszten	131
12	Inhibition of Gαi2 Activation by Gαi3 in CXCR3-mediated Signaling 2007 ·Journal of Biological Chemistry ·Brian Thompson, (unknown), (unknown), Richard A. Colvin, Andrew D. Luster, Lutz Birnbaumer, Mei X. Wu	49
13	Oligomerization of CXCL10 Is Necessary for Endothelial Cell Presentation and In Vivo Activity 2006 ·The Journal of Immunology ·Gabriele Campanella, Jan Grimm, (unknown), Richard A. Colvin, Benjamin D. Medoff, Gregory R. Wojtkiewicz, Ralph Weissleder, Andrew D. Luster	81
14	T-bet Controls Pathogenicity of CTLs in the Heart by Separable Effects on Migration and Effector Activity 2006 ·The Journal of Immunology ·Viviany R. Taqueti, Nir Grabie, Richard A. Colvin, Hong Pang, Petr Jarolı́m, Andrew D. Luster, Laurie H. Glimcher, Andrew H. Lichtman	52
15	Membrane‐bound eotaxin‐3 mediates eosinophil transepithelial migration in IL‐4‐stimulated epithelial cells 2006 ·European Journal of Immunology ·Qian Yuan, Gabriele Campanella, Richard A. Colvin, Daniel L. Hamilos, (unknown), Anuja Mathew, Terry K. Means, Andrew D. Luster	35
16	Intracellular Domains of CXCR3 That Mediate CXCL9, CXCL10, and CXCL11 Function 2004 ·Journal of Biological Chemistry ·Richard A. Colvin, Gabriele Campanella, (unknown), Andrew D. Luster	219
17	Crystal Structures of Oligomeric Forms of the IP-10/CXCL10 Chemokine 2003 ·Structure ·G. Jawahar Swaminathan, Daniel E. Holloway, Richard A. Colvin, (unknown), Anastassios C. Papageorgiou, Andrew D. Luster, K. Ravi Acharya	65
18	Lymphopenia in dialysis patients: a preliminary study indicating a possible role of apoptosis 2002 ·Clinical Nephrology ·Madhu Bhaskaran, Rajiv Ranjan, Hitesh H. Shah, (unknown), Richard A. Colvin, (unknown), (unknown), Nicholas Franki, (unknown), Pravin C. Singhal	9
19	CXCR3 Internalization Following T Cell-Endothelial Cell Contact: Preferential Role of IFN-Inducible T Cell α Chemoattractant (CXCL11) 2001 ·The Journal of Immunology ·Alain Sauty, Richard A. Colvin, Ludwig Wagner, (unknown), François Spertini, Andrew D. Luster	130
20	Structural features of the trans-activation response RNA element of equine infectious anemia virus 1993 ·Biochemistry ·David W. Hoffman, Richard A. Colvin, Mariano A. García-Blanco, Stephen W. White	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact